Industry News
Biota antiviral batters the common cold
Biota Holdings (ASX:BTA) has revealed the results of a successful phase IIb trial of its common cold treatment candidate, vapendavir. [ + ]
Alchemia finalising oncology spin-off
Brisbane-based Alchemia (ASX:ACL) is in the last stages of planning for the proposed spin-off and IPO of its oncology unit. [ + ]
iSonea to trial wheeze diagnostic in children
iSonea (ASX:ISN) will conduct a post-market trial of its WheezeoMeter diagnostics tool in patients too young for the traditional spirometry method. [ + ]
Australian Synchrotron beams on with $100m injection
$100 million in funding from the Australian, New Zealand and Victorian governments has saved the Australian Synchrotron from possible closure. [ + ]
Drug cocktail floors malaria
A combination treatment of anti-malarial drugs given intermittently over 12 months can cut malaria infections by up to 30 per cent in infants. [ + ]
Agreement secures future of the Australian Synchrotron
The future of one of the nation’s landmark research facilities - the Australian Synchrotron - has been secured under a $100 million agreement between the Australian and Victorian governments. [ + ]
Free listing on Australian biotech and medtech directories
AusBiotech invites Australian companies to list their biotechnology and medical technology companies free on two national directories. [ + ]
Research opens way for tailoring medications to patients
International research co-authored by the University of Otago, Christchurch (UOC) has unravelled a century-old scientific mystery, opening the way to significant improvements in the way drugs are delivered to the body. [ + ]
Australian Academy of Science elects new Fellows
The Australian Academy of Science has issued its annual list of new Fellows, admitting 21 more scientists to its ranks. [ + ]
Bioniche licenses animal health products
Canada-based Bioniche (ASX:BNC) has scored an exclusive distribution deal covering four products for its animal health-focused Australian subsidiary. [ + ]
Bionomics gets approval for ovarian cancer trial
Bionomics (ASX:BNO) has been cleared by the Food and Drug Administration to commence a phase I/II clinical trial of BNC105 as a treatment for ovarian cancer. [ + ]
Avexa closer to EMA approval for ATC
Avexa Limited (ASX:AVX) and the EMA have agreed on the path forward to gaining European approval for drug-resistant HIV treatment ATC. [ + ]
Australia ranked highly in science research output
Australia is a top performer when it comes to science output per capita and per scientist, according to the Nature Publishing Index 2011 Asia-Pacific. [ + ]
Research aims to reduce side effects of cancer treatment
The painful side effects of cancer treatment, including nausea and hair loss, could be a thing of the past, thanks to groundbreaking chemical research being conducted at the University of Canterbury. [ + ]
Starpharma kicks off phase III VivaGel trials
Melbourne's Starpharma Holdings (ASX:SPL) has commenced two phase III trials of VivaGel as a BV treatment, the results of which will be pivotal to its New Drug Application with the FDA. [ + ]
